Antonio Silvestri, Filippo Gavi, Maria Chiara Sighinolfi, Simone Assumma, Enrico Panio, Daniele Fettucciari, Giuseppe Pallotta, Or Schubert, Cristina Carerj, Mauro Ragonese, Pierluigi Russo, Riccardo Bientinesi, Nazario Foschi, Chiara Ciccarese, Roberto Iacovelli, Bernardo Rocco
{"title":"Management of Small Renal Masses: Literature and Guidelines Review.","authors":"Antonio Silvestri, Filippo Gavi, Maria Chiara Sighinolfi, Simone Assumma, Enrico Panio, Daniele Fettucciari, Giuseppe Pallotta, Or Schubert, Cristina Carerj, Mauro Ragonese, Pierluigi Russo, Riccardo Bientinesi, Nazario Foschi, Chiara Ciccarese, Roberto Iacovelli, Bernardo Rocco","doi":"10.1590/S1677-5538.IBJU.2025.0203","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) ranks among the most prevalent malignancies worldwide, with a rising incidence attributed largely to the incidental detection of small renal masses (SRMs ≤ 4 cm) through widespread abdominal imaging. Historically managed with radical nephrectomy, treatment of SRMs has evolved significantly over recent decades. Partial nephrectomy has become the standard surgical approach, while active surveillance (AS) has emerged as a viable alternative for select patients, particularly those with comorbidities or limited life expectancy. AS involves serial imaging to monitor tumor progression, reserving intervention for signs of clinical advancement. This review synthesizes oncological outcomes and current management strategies for SRMs, comparing AS with immediate intervention. A comprehensive literature search (2005-2024) was performed across PubMed, Web of Science, and Scopus, complemented by an analysis of major international guidelines (EAU, AUA, ESMO, CUA, and Latin American Renal Cancer Group). All guidelines support AS for selected patients with cT1a tumors, though criteria vary. The AUA limits AS to tumors <2 cm, while only its guidelines define clear triggers for transitioning from AS to treatment. Imaging surveillance intervals and biopsy indications also differ, with broader support for renal mass biopsy prior to ablation but more selective use during AS. This review underscores the importance of individualized decision-making in SRM management and highlights areas of consensus and divergence among contemporary guidelines.</p>","PeriodicalId":49283,"journal":{"name":"International Braz J Urol","volume":"51 5","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12539897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Braz J Urol","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/S1677-5538.IBJU.2025.0203","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Renal cell carcinoma (RCC) ranks among the most prevalent malignancies worldwide, with a rising incidence attributed largely to the incidental detection of small renal masses (SRMs ≤ 4 cm) through widespread abdominal imaging. Historically managed with radical nephrectomy, treatment of SRMs has evolved significantly over recent decades. Partial nephrectomy has become the standard surgical approach, while active surveillance (AS) has emerged as a viable alternative for select patients, particularly those with comorbidities or limited life expectancy. AS involves serial imaging to monitor tumor progression, reserving intervention for signs of clinical advancement. This review synthesizes oncological outcomes and current management strategies for SRMs, comparing AS with immediate intervention. A comprehensive literature search (2005-2024) was performed across PubMed, Web of Science, and Scopus, complemented by an analysis of major international guidelines (EAU, AUA, ESMO, CUA, and Latin American Renal Cancer Group). All guidelines support AS for selected patients with cT1a tumors, though criteria vary. The AUA limits AS to tumors <2 cm, while only its guidelines define clear triggers for transitioning from AS to treatment. Imaging surveillance intervals and biopsy indications also differ, with broader support for renal mass biopsy prior to ablation but more selective use during AS. This review underscores the importance of individualized decision-making in SRM management and highlights areas of consensus and divergence among contemporary guidelines.
肾细胞癌(RCC)是世界上最常见的恶性肿瘤之一,其发病率的上升主要归因于通过广泛的腹部影像学偶然发现的小肾肿块(SRMs≤4 cm)。从历史上看,srm的治疗方法是根治性肾切除术,近几十年来,srm的治疗方法有了显著的发展。部分肾切除术已成为标准的手术方法,而主动监测(AS)已成为选择性患者的可行选择,特别是那些有合并症或预期寿命有限的患者。AS包括一系列影像学检查以监测肿瘤进展,保留对临床进展迹象的干预。这篇综述综合了srm的肿瘤预后和当前的管理策略,比较了AS和立即干预。通过PubMed、Web of Science和Scopus进行了全面的文献检索(2005-2024),并对主要国际指南(EAU、AUA、ESMO、CUA和拉丁美洲肾癌组)进行了分析。尽管标准不同,但所有指南都支持选定的cT1a肿瘤患者采用AS。AUA限制了AS对肿瘤的影响